Enzymotec Ltd
ENZY
ENZY was delisted on the 10th of January, 2018.
25 hedge funds and large institutions have $108M invested in Enzymotec Ltd in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 12 closing their positions.
26% less funds holding
Funds holding: 34 → 25 (-9)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
43% less capital invested
Capital invested by funds: $187M → $108M (-$79.7M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
+$16.1M |
| 2 |
D.E. Shaw & Co
New York
|
+$5.1M |
| 3 |
MCM
Matterhorn Capital Management
San Antonio,
Texas
|
+$2.25M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$1.1M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$977K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AP
Alydar Partners
Boston,
Massachusetts
|
-$6.86M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$5.81M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$4.77M |
| 4 |
PA
Perceptive Advisors
New York
|
-$4.72M |
| 5 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
-$4.37M |
ENZY Hedge Fund Activity: Q2 2014 in Review
25 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q2 2014, worth a combined $108M — down 43% from $187M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ENZY and 3 opened new positions — a net loss of 9 holders — while 11 trimmed existing stakes and 8 added.
The largest buyer was Visium Asset Management, adding an estimated $16.1M. The largest seller was Alydar Partners, exiting entirely with an estimated $6.86M sold.
- 25 institutional investors held Enzymotec Ltd (ENZY) as of Q2 2014, down from 34 in Q1 2014.
- Funds reported $108M of Enzymotec Ltd stock for Q2 2014, down 43% quarter-over-quarter.
- 3 funds opened new Enzymotec Ltd positions in Q2 2014 and 12 closed out, a net change of -9 holders.
- The largest Enzymotec Ltd buyer in Q2 2014 was Visium Asset Management, an estimated $16.1M added.
- The largest Enzymotec Ltd seller in Q2 2014 was Alydar Partners, an estimated $6.86M sold.
Based on aggregated 13F filings for Q2 2014.